BR112014026407A2 - formulação de vacina líquida - Google Patents

formulação de vacina líquida

Info

Publication number
BR112014026407A2
BR112014026407A2 BR112014026407A BR112014026407A BR112014026407A2 BR 112014026407 A2 BR112014026407 A2 BR 112014026407A2 BR 112014026407 A BR112014026407 A BR 112014026407A BR 112014026407 A BR112014026407 A BR 112014026407A BR 112014026407 A2 BR112014026407 A2 BR 112014026407A2
Authority
BR
Brazil
Prior art keywords
vaccine
rotavirus
vaccine formulation
administration
buffers
Prior art date
Application number
BR112014026407A
Other languages
English (en)
Other versions
BR112014026407B1 (pt
Inventor
Mohan Vadrevu Krishna
Devarajulu Prasad Sai
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Publication of BR112014026407A2 publication Critical patent/BR112014026407A2/pt
Publication of BR112014026407B1 publication Critical patent/BR112014026407B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

resumo formulação de vacina líquida a invenção provê composições novas de vacina contra rotavírus compreendendo antígenos do rotavírus, estabilizadores e tampões. os tampões na invenção são pré- misturados nas composições de vacina contra rotavírus para neutralizar o ph altamente acídico do estômago sem a necessidade de administração separada de um antiácido antes da administração da vacina. as composições de vacina com tampões da invenção são formulações de vacina contra rotavírus líquidas estáveis para administração oral. 1/1
BR112014026407-4A 2012-04-23 2013-04-23 formulação de vacina líquida BR112014026407B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN667CH2012 2012-04-23
IN667/CHE/2012 2012-04-23
PCT/IN2013/000272 WO2013160913A1 (en) 2012-04-23 2013-04-23 Rotavirus vaccine compositions and process for preparing the same

Publications (2)

Publication Number Publication Date
BR112014026407A2 true BR112014026407A2 (pt) 2017-06-27
BR112014026407B1 BR112014026407B1 (pt) 2020-12-22

Family

ID=48808420

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014026407-4A BR112014026407B1 (pt) 2012-04-23 2013-04-23 formulação de vacina líquida

Country Status (7)

Country Link
US (1) US10568957B2 (pt)
EP (1) EP2945650B1 (pt)
JP (1) JP6126684B2 (pt)
CN (2) CN110227152A (pt)
BR (1) BR112014026407B1 (pt)
RU (1) RU2643929C2 (pt)
WO (1) WO2013160913A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018007413A (es) * 2015-12-18 2018-08-15 Merck Sharp & Dohme Formulaciones de vacuna contra rotavirus termicamente estable y metodos de uso de la misma.
MA44557B1 (fr) * 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CN110106291A (zh) * 2019-06-03 2019-08-09 中国食品药品检定研究院 猪圆环病毒1型病毒核酸参考品及其制备方法与应用
EP3980058A1 (en) * 2019-06-10 2022-04-13 Boehringer Ingelheim Animal Health USA Inc. Stabilized liquid live vaccine
CN113994925B (zh) * 2021-12-30 2022-04-26 北京赛尔富森生物科技有限公司 一种轮状病毒攻毒动物模型及其建立方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720460A (en) * 1985-04-04 1988-01-19 Miles Laboratories, Inc. Process for preserving acid producing bacteria and compositions produced thereby
US7150984B2 (en) * 1994-07-11 2006-12-19 The United States Of America As Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US5914135A (en) * 1997-04-16 1999-06-22 Mcneil-Ppc, Inc. Liquid antacid compositions
ES2260046T3 (es) 1999-08-17 2006-11-01 Glaxosmithkline Biologicals S.A. Procedimiento para separar variantes rotavirus y vacuna de rotavirus vivos atenuados.
EP1391513A1 (en) * 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
JP2006517913A (ja) * 2003-02-13 2006-08-03 ベクトン・ディキンソン・アンド・カンパニー 改良型炭疽ワクチンおよび送達方法
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
PE20070235A1 (es) * 2005-08-17 2007-04-04 Glaxosmithkline Biolog Sa Vacuna que contiene rotavirus atenuado
DE102006054260A1 (de) * 2006-02-28 2007-09-27 Lohmann Animal Health Gmbh & Co. Kg Wasser stabilisierende Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung
AU2007251122B2 (en) * 2006-05-12 2013-01-10 Bharat Biotech International Limited A composition useful as a vaccine
CA2681159A1 (en) * 2007-03-13 2008-09-18 Peros Systems Technologies, Inc. Immunoactive compositions for improved oral delivery of vaccines and therapeutic agents
US8241886B2 (en) * 2007-09-25 2012-08-14 Aridis Pharmaceuticals Formulations for preservation of rotavirus
BRPI1012170A2 (pt) * 2009-05-20 2016-03-29 Lingual Consegna Pty Ltd formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido.
BR112012000588A2 (pt) 2009-07-13 2020-08-11 Bharat Biotech International Limited composição, composição líquida, composição liofilizada e método para produzir um rotavirus atenuado
US20110243988A1 (en) * 2009-10-01 2011-10-06 Aridis Pharmaceuticals Methods and Compositions for Stabilization of a Virus Vaccine
EP3225247B1 (en) * 2010-05-28 2020-09-02 3M Innovative Properties Company Aqueous formulations for coating microneedle arrays

Also Published As

Publication number Publication date
EP2945650B1 (en) 2023-07-05
CN104507495A (zh) 2015-04-08
US10568957B2 (en) 2020-02-25
US20150098967A1 (en) 2015-04-09
WO2013160913A1 (en) 2013-10-31
JP6126684B2 (ja) 2017-05-10
CN110227152A (zh) 2019-09-13
JP2015514750A (ja) 2015-05-21
RU2643929C2 (ru) 2018-02-06
BR112014026407B1 (pt) 2020-12-22
EP2945650A1 (en) 2015-11-25
RU2014146772A (ru) 2016-06-10

Similar Documents

Publication Publication Date Title
CY1119918T1 (el) Συνθεσεις γαμμα-υδροξυβουτυρικου και η χρηση τους για την αντιμετωπιση διαταραχων
BR112014026407A2 (pt) formulação de vacina líquida
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
CO6680698A2 (es) Formulación de premezcla de dexmedetomidina
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
TR201908003T4 (tr) TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
EA201500742A1 (ru) Защищенные от нецелевого использования фармацевтические композиции
ECSP12011803A (es) Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
BR112012012862A2 (pt) composição farmacêutica compreendendo oligopeptídeos
MX2013003635A (es) Compuestos de n-heteroarilo.
BRPI0915119B8 (pt) uso de iota carragenano
EA201592003A1 (ru) Микропищевые добавки для иммунитета
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
TR201821157T4 (tr) İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m.
BR112017009510A2 (pt) composições compreendendo ciclosporina
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/04/2013, OBSERVADAS AS CONDICOES LEGAIS.